Alkem Laboratories Limited

rs,

04th February, 2022 The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange of India Limited Excha

26,190 million

mbai today. Key highlights of Q3FY22 financial performance • Total Revenue from Operations was~ 26,190 million, year-on-year growth of 13.0% o o India sales were~ 18,156 million, year-on-year growth of 19

13.0%

financial performance • Total Revenue from Operations was~ 26,190 million, year-on-year growth of 13.0% o o India sales were~ 18,156 million, year-on-year growth of 19.9% International sales were

18,156 million

venue from Operations was~ 26,190 million, year-on-year growth of 13.0% o o India sales were~ 18,156 million, year-on-year growth of 19.9% International sales were~ 7,709 million, year-on-year decline of 0.

19.9%

on, year-on-year growth of 13.0% o o India sales were~ 18,156 million, year-on-year growth of 19.9% International sales were~ 7,709 million, year-on-year decline of 0.4% • Earnings before Interes

7,709 million

o o India sales were~ 18,156 million, year-on-year growth of 19.9% International sales were~ 7,709 million, year-on-year decline of 0.4% • Earnings before Interest, Tax, Depreciation and Amortization (EBI

0.4%

on, year-on-year growth of 19.9% International sales were~ 7,709 million, year-on-year decline of 0.4% • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ~ 4,985 million, re

4,985 million

ear decline of 0.4% • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ~ 4,985 million, resulting in EBITDA margin of 19.0% vs. 22 .8% in Q3FY21. EBITDA declined by 5.8% YoY • R&D ex

19.0%

t, Tax, Depreciation and Amortization (EBITDA) was ~ 4,985 million, resulting in EBITDA margin of 19.0% vs. 22 .8% in Q3FY21. EBITDA declined by 5.8% YoY • R&D expenses for the quarter was~ 1,449 milli

8%

iation and Amortization (EBITDA) was ~ 4,985 million, resulting in EBITDA margin of 19.0% vs. 22 .8% in Q3FY21. EBITDA declined by 5.8% YoY • R&D expenses for the quarter was~ 1,449 million, or 5.5%

5.8%

was ~ 4,985 million, resulting in EBITDA margin of 19.0% vs. 22 .8% in Q3FY21. EBITDA declined by 5.8% YoY • R&D expenses for the quarter was~ 1,449 million, or 5.5% of total revenue from operations

1,449 million

in of 19.0% vs. 22 .8% in Q3FY21. EBITDA declined by 5.8% YoY • R&D expenses for the quarter was~ 1,449 million, or 5.5% of total revenue from operations compared to~ 1,335 million in Q3FY21 at 5.8% of total r

Details of the conference call are as under

1

Dial in Details

1

Dial in Details

India : +91 22 6280 1149 / +91 22 7115 8050 International Toll Free USA UK Singapore Hong Kong : 1 866 746 2133 : 0 808 1011573 : 800 1012045 : 800 964 448 Express Join with Diamond Pass https://services .choruscall.in/DiamondPassRegistration/reqfster?confirmationNumber=7734368&linkS ecu rityS tri nq= 1 f6089c600 You are requested to dial in 10 mins ahead of the scheduled start time. A transcript of this conference call will also be available on our website www.alkemlabs.com Ab out Alkem Laboratories Ltd . Established in 1973 and headquartered in Mumbai, Alkem (NSE : ALKEM, SSE : 539523, Bloomberg: ALKEM .IN, Reuters: ALKE .NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APls) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800